Genetic testing for the clinician in prostate cancer.

Fernando López-CamposEstefanía Linares-EspinósXavier Maldonado-PijoanGemma Sancho PardoTodd Mathew MorganClaudio Martínez-BallesterosJuan Martínez-SalamancaFelipe Couñago

Published in: Expert review of molecular diagnostics (2020)

There is a growing need for molecular testing to identify the most indolent types of prostate cancer to help optimize treatment strategies and spare treatment in these patients when possible. Current trends in the treatment of prostate cancer underscore the unmet clinical need for biomarkers to improve decision-making in a challenging clinical setting.

Keyphrases

prostate cancer
radical prostatectomy
end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
combination therapy
hodgkin lymphoma